Targets › COL2A1
1 program from 1 company in 6 trials: 5 Phase 4, 1 Phase 3; Genitourinary, Other; next expected readout Dec 2027.
Type II collagen is specific for cartilaginous tissues. It is essential for the normal embryonic development of the skeleton, for linear growth and for the ability of cartilage to resist compressive forces. (UniProt, P02458)
Open in Phaseline: the race on COL2A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Endo USA Inc., a Keenova Therapeutics Company | Collagenase Clostridium Histolyticum (KN3835) Collagen hydrolytic enzyme | COL1A2, COL1A1, COL2A1, COL3A1, COL4A1 | Phase 3 | Flexible Hammertoe; Peyronie Disease; Peyronie's Disease; Dupuytren Disease of Finger … | Dec 2027 |
Peyronie Disease (2) Flexible Hammertoe (1) Peyronie's Disease (1) Dupuytren Disease of Finger (1) Dupuytren Contracture (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.